Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
Latest Information Update: 16 Sep 2022
At a glance
- Drugs VB 201 (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms VITAL HIV Trial
- 12 Sep 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Jun 2021 New trial record